

Review Form 1.6

Journal Name:	International Journal of Research and Reports in Hematology
Manuscript Number:	Ms_IJR2H_82797
Title of the Manuscript:	Rituximab induced late onset neutropenia
Type of the Article	Case study

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journalijr2h.com/index.php/IJR2H/editorial-policy>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments	Abstract, paragraph 4, line 1-2: it is true that LON could appear several months after completion of therapy, however timing of LON onset should be specified. LON is more common in the first year after completion of Rituximab and its incidence rate decreases after this period. Case report, paragraph 4, line 5-6: if the diagnosis is neutropenic fever, Meropenem dosage indicated is of 500mg/1000mg every 8h. In case of protocols specific for a particular Institution, this choice should be specified.	Added (1 to 5 months) after several months in the abstract . Highlighted in yellow. Thank you very much for showing tis. We did give at 500 mg 8 hrly. Changed to IV Meropenem 500mg tds . Highlighted in yellow
<u>Minor</u> REVISION comments	Introduction, paragraph 9, line 4: minor orthography issue. Case report, paragraph 2, line 1: minor grammatical issue. Case report, paragraph 4, line 8-9: please rephrase. Discussion, paragraph 2, line 1-2: please rephrase.	Changed nonhodgkin lymphoma to non hodgkin's lymphoma 'to which he ' replaced with ' but ' 'and further to' replaced with . The counts were Late-onset neutropenia has been reported in 5–27% lymphoma patients by a number of groups,[7–16] replaced with The incidence of LON occurring in patients treated for lymphomas is 5-27% [7-16]
<u>Optional/General</u> comments	Case report is well constructed and very interesting. Reports of cases of rare diseases and complications are useful in clinical practice to help colleagues to face this conditions.	

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	